Univariate analysis of factors associated with occurrence of zoster in the year after exposure to pulse intravenous CYC for systemic vasculitis or SLE (n = 110). Values are n (%) unless otherwise specified.
| Variables | Without Zoster Occurrence, n = 104 | With Zoster Occurrence, n = 6 | HR (95% CI) | p |
|---|---|---|---|---|
| SLE vs vasculitis | 26 (25.0) | 3 (50.0) | 2.68 (0.54–13.26) | 0.23 |
| Age ≥ 50 yrs | 65 (62.5) | 4 (66.7) | 1.26 (0.23–6.90) | 0.79 |
| Females | 55 (52.9) | 5 (83.3) | 4.36 (0.51–37.31) | 0.18 |
| Antecedents | ||||
| Diabetes | 8 (7.7) | 0 | – | – |
| Cancer | 6 (5.8) | 0 | – | – |
| Renal failure at CYC initiation a | 49 (49.5) b | 3 (50.0) | 1.01 (0.20–5.01) | 0.99 |
| Lymphopenia at CYC initiation | ||||
| < 1000/µl | 33 (33.3) b | 3 (50.0) | 1.89 (0.38–9.35) | 0.44 |
| < 500/µl | 7 (7.1) b | 2 (33.3) | 5.11 (0.94–27.93) | < 0.06 |
| Exposure to IS before CYC | 24 (23.1) | 2 (33.3) | 1.58 (0.29–8.65) | 0.59 |
| Concomitant exposure to CS | 104 (100) | 6 (100) | – | – |
| CYC cumulative dose > 3 g c | 69 (71.9) d | 4 (66.7) | 0.73 (0.13–4.01) | 0.72 |
| Prophylaxis by valacyclovir | 19 (18.2) | 0 | – | – |
↵a Renal failure: glomerular filtration rate < 60 ml/min at first CYC infusion.
↵b Missing values in 5 patients.
↵c Median value of CYC cumulative dose in the cohort.
↵d Missing values in 8 patients. CS: corticosteroids; CYC: cyclophosphamide; IS: immunosuppressive drugs (excluding corticosteroids); SLE: systemic lupus erythematosus.